Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Pharmacother. 2014 Aug;48(8):1019-1029. Epub 2014 May 8.

Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.

Author information

1
Western New England University, Springfield, MA, USA lrose@wne.edu.
2
Hahnemann University Hospital, Philadelphia, PA, USA.
3
Western New England University, Springfield, MA, USA.
4
Drexel University College of Medicine, Philadelphia, PA, USA.
5
MCPHS University-Worcester/Manchester, Worcester, MA, USA.

Abstract

OBJECTIVE:

To review the use of sofosbuvir for the treatment of chronic hepatitis C virus (HCV).

DATA SOURCES:

Review and nonreview articles were identified through MEDLINE (1996-April 2014), citations of articles, and meeting abstracts using keywords, including NS5B polymerase inhibitor, GS-7977, sofosbuvir, direct-acting antiviral (DAA), and others.

STUDY SELECTION AND DATA EXTRACTION:

Phase 1, 2, and 3 studies describing dose-ranging potential, pharmacokinetics, efficacy, safety, and tolerability of sofosbuvir were identified.

DATA SYNTHESIS:

Sofosbuvir is an NS5B polymerase inhibitor that was approved for use by the Food and Drug Administration in December 2013 for the treatment of chronic HCV in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) for genotype 1. Additionally, it has been evaluated with other oral DAAs, such as simeprevir and others in the pipeline. It is not recommended as monotherapy because of lower sustained virological response (SVR) rates in clinical studies. Most of the treatment regimens are 12 weeks in duration; however, certain populations require a longer duration. Sofosbuvir has activity against all 6 genotypes, although most clinical trials evaluated genotypes 1 to 3. Sofosbuvir has a favorable safety and tolerability profile, making it a recommended first-line agent for chronic HCV infection.

CONCLUSION:

In clinical trials, 12 weeks of sofosbuvir with concomitant peg-IFN and RBV therapy in treatment-naïve and experienced HCV genotype 1 patients resulted in SVR rates of >90%. An all-oral regimen of sofosbuvir and RBV is highly effective for genotype 2 and 3 patients. Sofosbuvir was found to be tolerable with minimal adverse effects (AEs), and no treatment discontinuations occurred secondary to drug related AEs..

KEYWORDS:

GS-7977; NS5B polymerase inhibitor; chronic hepatitis C infection; sofosbuvir

PMID:
24811396
DOI:
10.1177/1060028014534194
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center